Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesity and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans.
Research in the Jeanne Clark Lab covers a wide range of fields, employing various research techniques, methods and procedures to generate and disseminate the knowledge required to prevent disease and its consequences. Our most recent research program, Look AHEAD, focuses on the health of overweight volunteers with type 2 diabetes. We are examining the long-term effects of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity.
The Nestoras Mathioudakis Lab focuses on improving patient safety and quality for hospitalized diabetes patients. Our interests include inpatient glucose management, type 2 diabetes mellitus and diabetic foot ulcers.
Our research interest is crystalized into three main areas:
1. Type-1 diabetes - Our focus is on understanding how the Fas death pathway regulates the disease and how extracted information can be used to protect high risk individuals and those with new-onset disease.
2. Type 2 diabetes and Obesity - Our lab is studying the role of heparan sulfate proteoglycans (HSPG) in regulating body fat and glucose clearance.
3. Double negative ??T cells - Our studies suggest a critical role for these cells in protecting kidneys from Ischemia reperfusion injury (IRI). Our current focus is understanding their origin and physiological functions.
The Thomas W. Donner Lab focuses on type 1 and type 2 diabetes, with an emphasis on the prevention of complications in patients with these conditions. We’re currently collaborating with Dr. Abdel Hamad to inhibit B-regulatory cell apoptosis through a novel monoclonal antibody that targets the probable apoptotic factor. We also lead a multi-center, international consortium of researchers studying ways to prevent type 1 diabetes and preserve insulin secretion in people who have been recently diagnosed with the chronic condition.